Abstract：
Neoadjuvant chemotherapy (NAC) is the preferred treatment option in locally advanced breast cancer (BC). The administration of NAC is associated with a wide range of adverse effects. This pilot observational prospective study examined the effect of NAC using anthracycline + cyclophosphamide (AC) followed by paclitaxel (PTx) on a portfolio of 22 plasma and urinary amino acids, plasma proteins (albumin, prealbumin, transferrin), and products of nitrogen metabolism (urea, creatinine, uric acid) in plasma and urine. Plasma and 24-h urine samples were obtained from ten patients with early breast cancer (N1-3 N0-2 M0), at the following time points: before the start of NAC and during the AC/PTx treatment period (a total of 8 measurements at three-weekly intervals). Amino acids were analyzed using ion exchange chromatography. There were no significant differences in the measured parameters in plasma and urine between pre-NAC and during AC- and PTx-treatment. No trend was detected. A significant difference in the portfolio of plasma and urinary amino acids was found only in the pre-treatment period compared to the control group. Levels of eight plasma amino acids (8/22) were significantly reduced and those of nine urine amino acids were increased (9/22). Nitrogenous catabolites in plasma and urine were not indicative of increased protein catabolism during the anthracycline and taxane treatment periods. A slightly positive nitrogen balance was accompanied by an average weight gain of 3.3 kg (range 0-6 kg). The AC/PTx treatment regimen did not cause significant changes in the monitored laboratory parameters.
摘要：
新辅助化疗（NAC）是局部晚期乳腺癌（BC）的首选治疗选择。NAC的给药与广泛的不良反应相关。这项实验性观察性前瞻性研究检查了使用蒽环类抗生素环磷酰胺（AC）和紫杉醇（PTx）的NAC对22种血浆和尿氨基酸组合的影响。血浆蛋白(白蛋白，前白蛋白,转铁蛋白)，和氮代谢产物(尿素，肌酐,尿酸）在血浆和尿液中。从10例早期乳腺癌患者（N1-3N0-2M0）获得血浆和24小时尿液样本，在以下时间点：NAC开始之前和AC/PTx治疗期间（每周间隔共8次测量）。使用离子交换色谱法分析氨基酸。在NAC之前以及AC和PTx治疗期间，血浆和尿液中的测量参数没有显着差异。未检测到趋势。与对照组相比，仅在治疗前发现血浆和尿中氨基酸的组合存在显着差异。8种血浆氨基酸（8/22）水平显着降低，9种尿液氨基酸水平升高（9/22）。在蒽环类和紫杉烷治疗期间，血浆和尿液中的含氮分解代谢物并未表明蛋白质分解代谢增加。轻微的正氮平衡伴随着3.3kg的平均体重增加(范围0-6kg)。AC/PTx治疗方案没有引起监测的实验室参数的显著变化。
